



## UroGen Pharma to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021

May 6, 2021

*Conference Call and Webcast Scheduled for Thursday, May 13, 2021 at 8:30 AM ET*

PRINCETON, N.J.--(BUSINESS WIRE)--May 6, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will report first quarter 2021 financial results on Thursday, May 13, 2021, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 8:30 AM Eastern Time.

### Audio Webcast

The webcast will be made available on the Investors section of the Company's website at <http://investors.urogen.com>. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.

### Dial-In Information

Live (U.S. / Canada): (855) 765-5685

Live (International): (615) 247-5916

Confirmation number: 5768352

### About UroGen Pharma Ltd.

UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen's first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit [www.urogen.com](http://www.urogen.com) to learn more or follow us on Twitter, @UroGenPharma.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210506005066/en/): <https://www.businesswire.com/news/home/20210506005066/en/>

### INVESTOR CONTACTS:

Sara Blum Sherman  
Head of Investor Relations  
[investors@urogen.com](mailto:investors@urogen.com)

Lee Roth  
[lroth@burnsmc.com](mailto:lroth@burnsmc.com)  
212-213-0006

### MEDIA CONTACT:

Eric Van Zanten  
Head of Communications  
[Eric.VanZanten@urogen.com](mailto:Eric.VanZanten@urogen.com)  
610-529-6219

Source: UroGen Pharma Ltd.